Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Filed Jul 31, 2026 · 10-Q · 31 days after period end · 0000899923-26-000072
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $190.70M | $213.10M | $211.50M | $183.50M |
| Net Income | -$43.20M | -$330.50M | -$36.70M | -$116.10M |
| EPS Diluted | -$0.46 | -$3.57 | -$0.41 | -$1.42 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Jul 31, 2026 · 31 d after period end
